Effect of a novel agent, SL-401, targeting interleukin-3 receptor (IL-3R) on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and osteolytic bone disease.
Dharminder Chauhan
Consultant or Advisory Role - Stemline Therapeutics
Arghya Ray
No relevant relationships to disclose
Deepika Sharma Das
No relevant relationships to disclose
Vincent Macri
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics
Christopher Brooks
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics
Paul G. Richardson
No relevant relationships to disclose
Eric K. Rowinsky
Employment or Leadership Position - Stemline Therapeutics
Stock Ownership - Stemline Therapeutics
Kenneth Carl Anderson
No relevant relationships to disclose